A5083429598- Respiratory viral infections research
- Herpesvirus Infections and Treatments
- Protein Kinase Regulation and GTPase Signaling
- Poxvirus research and outbreaks
- Pneumonia and Respiratory Infections
- HIV Research and Treatment
- Alkaline Phosphatase Research Studies
- Cytomegalovirus and herpesvirus research
- Influenza Virus Research Studies
- HIV/AIDS drug development and treatment
- Immune Response and Inflammation
- Tracheal and airway disorders
- Congenital Diaphragmatic Hernia Studies
- Ion channel regulation and function
- Rabies epidemiology and control
- HIV/AIDS Research and Interventions
- Acne and Rosacea Treatments and Effects
- ATP Synthase and ATPases Research
- Mitochondrial Function and Pathology
- Algal biology and biofuel production
- Cutaneous Melanoma Detection and Management
- Virology and Viral Diseases
- Biochemical and Molecular Research
- Blood Coagulation and Thrombosis Mechanisms
- Cellular transport and secretion
GlaxoSmithKline (Belgium)
2014-2025
GlaxoSmithKline (United States)
2014
KU Leuven
1986-1988
A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and AS01B adjuvant system was associated with a risk 97.2% lower than placebo. second performed concurrently at same sites examined safety efficacy HZ/su in 70 (ZOE-70).This randomized, placebo-controlled, phase 3 conducted 18 countries involved older. Participants received two doses placebo (assigned 1:1 ratio)...
Objective: Present 96-week data from ongoing ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In Naive Subjects) trial. Methods: Randomized, open-label, phase III trial of antiretroviral-naive patients HIV-1 RNA at least 5000 copies/ml (stratified by and CD4 cell count) receiving darunavir/ritonavir (DRV/r) 800/100 mg once daily or lopinavir/ritonavir (LPV/r) 800/200 total dose (twice daily) fixed-dose tenofovir/emtricitabine. Primary outcome measure was noninferiority DRV/r vs. LPV/r in...
The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing the ZOE-50 ZOE-70 trials. We present immunogenicity results from those Participants (ZOE-50: ≥50; ZOE-70: ≥70 years age) received 2 doses HZ/su or placebo, months apart. Serum anti-gE antibodies CD4 T cells expressing ≥2 4 activation markers assessed (CD42+) after stimulation with gE-peptides were measured subcohorts for humoral...
Abstract Background The aim of this study was to investigate safety and immunogenicity vaccine formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion conformation RSV fusion protein (RSVPreF3). Methods This phase 1/2, randomized controlled, observer-blind enrolled 48 young adults (YAs; aged 18–40 years) 1005 older (OAs; 60–80 between January August 2019. Participants were into equally sized groups receive 2 doses unadjuvanted (YAs OAs) or AS01-adjuvanted...
In phase III trials, 2 doses of a herpes zoster (HZ) subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) administered 2-months apart in older adults (≥50 ≥70 years) demonstrated >90% efficacy preventing HZ had clinically acceptable safety profile. Here we report immunogenicity, reactogenicity following administration HZ/su at intervals longer than months. this Phase III, open-label trial conducted the US Estonia, 354 ≥50 years were randomized...
The RSVPreF3-AS01 vaccine, containing the respiratory syncytial virus (RSV) prefusion F protein and AS01 adjuvant, was previously shown to boost neutralization responses against historical RSV strains be efficacious in preventing RSV-associated lower tract diseases older adults. Although is highly conserved, variation does exist between strains. Here, we characterized variations major viral antigenic sites among contemporary sequences when compared with RSVPreF3 showed that, adults, broadly...
Abstract Background In the previous (parent) study, 2 doses of different formulations an investigational vaccine against respiratory syncytial virus (RSVPreF3 OA) were well tolerated and immunogenic in older adults. This multicenter phase 2b extension study assessed safety immunogenicity a revaccination (third) dose 120 μg RSVPreF3-AS01E formulation. Methods total, 122 adults (60–80 years), previously vaccinated with (containing 30, 60, or RSVPreF3 antigen), received additional 18 months...
Abstract Background In a phase 3 study, the approved RSVPreF3 OA vaccine, administered as single dose in adults aged ≥ 60 years, has demonstrated high efficacy against RSV disease and was well tolerated with favorable safety profile. Here we present immunogenicity results older of different age frailty status from same study. Methods This 3, placebo-controlled, observer-blind, multi-country study (NCT04886596) enrolled years who were randomized (1:1) to receive or placebo, before season....
Genomic profiling of tumor tissue may identify gene signatures (GS) predictive response to treatment. We prospectively evaluated a GS linked clinical benefit following MAGE-A3 immunotherapeutic in patients with advanced melanoma. One-year overall survival was similar and without the GS: not outcome after treatment.BackgroundGenomic aid identifying or prognostic some cancers. Retrospective expression melanoma non-small-cell lung cancer led characterization associated benefit, including...
An AS03-adjuvanted H5N1 influenza vaccine elicited broad and persistent immune responses with an acceptable safety profile up to 6 months following the first vaccination in children aged 3-9 years.In this follow-up of Phase II study, we report immunogenicity persistence at 24 post-vaccination years. The randomized, open-label study assessed two doses A/Vietnam/1194/2004 (1·9 μg or 3·75 hemagglutinin antigen) formulated AS03A AS03B (11·89 mg 5·93 tocopherol, respectively). Control groups...
Background The effect of HIV type-1 (HIV-1) subtype on in vitro susceptibility and virological response to darunavir (DRV) lopinavir (LPV) was studied using a broad panel primary isolates, recombinant clinical isolates from treatment-naive, HIV-1-infected patients the Phase III trial, AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects (ARTEMIS). Methods Patients received DRV/ritonavir (DRV/r) 800/100 mg once daily ( n=343) or LPV/ritonavir (LPV/r) 800/200 total dose n=346), plus...
ABSTRACT From an experimental set‐up with boundary conditions of extended initial distribution the diffusion coefficient for glucose in a high K‐content carrageenan gel was evaluated as function concentration (1, 2 and 4%) temperature (0.0, 5.0, 10.0, 15.0, 25.0, 36.0°C). According to Arrhenius‐type equation, activation energies at 1, 4% were calculated 18.1, 17.4, 19.1 kJ/mol. these data it concluded that affects mainly by obstruction effect.
There is a need for better vaccines and vaccine strategies to reduce the burden of influenza in very young children. This phase 1, open-label study assessed reactogenicity, safety, immunogenicity an inactivated trivalent (TIV) containing low doses hemagglutinin antigen (7.5 µg each strain), adjuvanted with tocopherol-based oil-in-water emulsion Adjuvant System (AS03). Influenza vaccine-naïve children aged 6-35 months were sequentially enrolled receive TIV-AS03D (1.48 mg tocopherol) or...
The risk of developing herpes zoster (HZ) increases with age and is thought to be associated a decrease in cell-mediated immunity older adults. adjuvanted varicella-zoster virus (VZV) glycoprotein E (gE) recombinant subunit vaccine (HZ/su) showed >90% efficacy the prevention HZ when administered adults ≥50 years age. Here we aim evaluate immunogenicity consistency 3 different HZ/su lots assess safety these lots.This multicenter, phase III, double-blind, randomized study (NCT02075515),...
Background.Two doses of a candidate herpes zoster (HZ) subunit vaccine (HZ/ su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01 B Adjuvant System) administered 2 months (mo) apart in adults ≥50 years age demonstrated >90% efficacy preventing HZ had clinically acceptable safety profile.Here we report immunogenicity HZ/su at intervals longer than mo.Methods.In this phase III, open-label trial (NCT01751165) conducted the United States Estonia, 354 were randomized 1:1:1 to receive 0,2...
Myelin basic protein (MBP) reduces the amount of phosphatase activity produced in kinase F A ‐mediated activation ATP,Mg‐dependent phosphatase. MBP was shown not only to inhibit activated enzyme, but also impair inactive In addition prevents time‐dependent inactivation catalytic subunit by modulator protein. These observations point a regulatory role for reversible ATP, Mg‐dependent .
The activation of the ATP,Mg-dependent protein phosphatase [Fc.M] has been shown to involve a transient phosphorylation modulator subunit (M) and consequent isomerization catalytic (Fc) into its active conformation (Jurgensen, S., Shacter, E., Huang, C. Y., Chock, P. B., Yang, S. -D., Vandenheede, J. R., Merlevede, W. (1984) Biol. Chem. 259, 5864-5870). constitutes inactivating force for enzyme, but slow intramolecular inactivation can be prevented or blocked by addition either...
Polyclonal antibodies raised against the modulator protein of ATP,Mg‐dependent phosphatase completely neutralize all known properties purified modulator: inhibition or inactivation catalytic subunit as well kinase F A ‐mediated activation phosphatase. They do not cross‐react with phosphoinhibitor‐1 subunit. Direct analysis boiled unboiled skeletal muscle extracts by Western blotting reveals a 32 kDa polypeptide corresponding to most dominant staining band.
The dephosphorylation of the modulator subunit is an essential step in kinase FA-mediated activation ATP,Mg-dependent protein phosphatase. Mg2+ implicated this autocatalytic which not effected by addition phosphoinhibitor-1. Dephosphorylation free catalytic also largely Mg2+-dependent but can be abolished phosphoinhibitor-1 concentrations comparable to amount used as substrate (micromolar). phosphorylase phosphatase activity inhibited nanomolar and completely independent divalent cations.